Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:affiliatedWith |
gptkb:ABC_Research_Center
|
| gptkbp:built |
regulatory hurdles
|
| gptkbp:campusFacilities |
gptkb:XYZ_University
|
| gptkbp:chemicalFormula |
stable under normal conditions
thiazole derivatives C12H15N3O2S contains thiazole rings |
| gptkbp:clinicalTrials |
NCT01234567
Phase I, Phase II, Phase III potential treatment for autoimmune diseases |
| gptkbp:collaborations |
with pharmaceutical companies
ongoing with international teams |
| gptkbp:community_service |
measures of efficacy
|
| gptkbp:compatibleWith |
exhibits anti-inflammatory properties
|
| gptkbp:competitors |
high potential in therapeutics
|
| gptkbp:composedOf |
multi-step organic synthesis
|
| gptkbp:contraindication |
headaches reported
|
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:drugInterdiction |
none reported yet
moderate absorption |
| gptkbp:enrollment |
adults
|
| gptkbp:environmental_impact |
low toxicity
|
| gptkbp:funding |
government grant
joint funding with biotech firms |
| gptkbp:future_plans |
exploration of new formulations
|
| https://www.w3.org/2000/01/rdf-schema#label |
RXT (O)
|
| gptkbp:impact |
may cause nausea
|
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:judgingCriteria |
HPLC
|
| gptkbp:market |
not yet available
|
| gptkbp:number_of_stages |
Phase II
|
| gptkbp:nutritionalValue |
liver metabolism
|
| gptkbp:operational_status |
under clinical trials
|
| gptkbp:origin |
N-(4-(2-(4-(trifluoromethyl)phenyl)thiazol-4-yl)thiazol-2-yl)phenyl)acetamide
|
| gptkbp:patentAssignee |
PharmaCorp
|
| gptkbp:patentStatus |
patented compound
|
| gptkbp:publications |
multiple peer-reviewed articles
|
| gptkbp:regulatoryBody |
high affinity for target receptors
|
| gptkbp:regulatoryCompliance |
pending
|
| gptkbp:related_to |
other thiazole derivatives
|
| gptkbp:releaseYear |
2010
|
| gptkbp:research_focus |
anti-cancer properties
|
| gptkbp:researchAndDevelopment |
promising results in preclinical studies
|
| gptkbp:route |
oral
|
| gptkbp:safety_features |
requires further testing
|
| gptkbp:safetyFeatures |
ongoing during trials
|
| gptkbp:targets |
specific receptors in the body
|
| gptkbp:triggerType |
inhibits specific enzymes
|
| gptkbp:uses |
research in pharmacology
|
| gptkbp:waterManagement |
urinary excretion
|
| gptkbp:weight |
273.34 g/mol
|